# Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

> **NCT04617522** · PHASE1 · RECRUITING · sponsor: **Gilead Sciences** · enrollment: 30 (estimated)

## Conditions studied

- Advanced or Metastatic Solid Tumor
- Liver Failure

## Interventions

- **DRUG:** Sacituzumab Govitecan-hziy

## Key facts

- **NCT ID:** NCT04617522
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-06
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04617522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04617522, "Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04617522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*